Welcome to our dedicated page for Scynexis SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.
SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.
SCYNEXIS, Inc. held a special stockholder meeting where investors approved an amendment to its certificate of incorporation to implement a reverse stock split and decrease authorized shares. Stockholders cast 44,826,378 votes for the proposal, 6,708,960 against, and 102,965 abstaining, out of 79,442,633 shares entitled to vote.
Following this approval, the Board chose a one-for-eight reverse stock split ratio, effective May 29, 2026. Every 8 issued and outstanding shares of common stock will convert into 1 share, and authorized common shares will be reduced from 150,000,000 to 18,750,000 without changing par value.
The reverse split will proportionately affect all existing shares, as well as the share counts under equity compensation plans, options, RSUs, and warrants, with corresponding increases in option and warrant exercise prices. No fractional shares will be issued; holders entitled to fractions will receive cash instead. SCYNEXIS common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on June 1, 2026 under the existing ticker SCYX, with a new CUSIP number 811292 309.
SCYNEXIS, Inc. ownership disclosure: CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 3,956,319 shares, representing 6.2% of the common stock. The reported holdings consist of 2,086,960 Shares plus Shares issuable upon exercise of warrants; certain Warrants are exercisable only to the extent they do not cause holdings to exceed 4.99% or 9.99%. Shares outstanding were 62,051,330 as of March 31, 2026. Heights Capital serves as investment manager to CVI and may exercise voting and dispositive power over the reported Shares.
SCYNEXIS, Inc. reported a Q1 2026 net loss of $21.3 million, widening from $5.4 million a year earlier, mainly due to an $8.0 million in-process R&D charge for acquiring SCY-770 and higher operating costs. Research and development expense rose to $12.4 million, while selling, general and administrative expense increased to $4.6 million, including $0.8 million of financing-related costs. A warrant fair value loss of $5.2 million also weighed on results. Cash, cash equivalents and investments were $72.4 million as of March 31, 2026, supported by a March 2026 private placement with gross proceeds of $40.0 million. The company believes these resources fund operations for at least 12 months and is advancing SCY‑770 for autosomal dominant polycystic kidney disease and SCY‑247 for invasive fungal infections.
SCYNEXIS, Inc. filed a prospectus for the resale of up to 87,000,000 shares of Common Stock by the selling stockholders. The 87,000,000 shares comprise 34,750,000 outstanding shares, 8,750,000 Pre-Funded Warrant shares and 43,500,000 Common Warrant shares.
The company will not receive proceeds from these resales, except for cash exercises of the Pre-Funded Warrants at $0.0001 per share and Common Warrants at $1.20 per share. The shares were issued in a March 30, 2026 private placement at purchase prices of $0.92 per share with accompanying warrants and $0.9199 per Pre-Funded Warrant with accompanying warrants. The registration was filed to satisfy registration rights in the Purchase Agreement and related Registration Rights Agreement.
SCYNEXIS, Inc. registered up to 87,000,000 shares of Common Stock for resale by the purchasers in its March-April 2026 private placement (the "Selling Stockholders"). The registration covers 34,750,000 outstanding shares, 8,750,000 Pre-Funded Warrant shares and 43,500,000 Common Warrant shares issuable upon exercise.
The company will not receive proceeds from resales, except for any cash exercises of Pre-Funded Warrants at $0.0001 per share and Common Warrants at $1.20 per share. Shares outstanding were 79,442,633 as of April 1, 2026. The Common Stock last traded at $0.93 on April 30, 2026.
SCYNEXIS, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 25, 2026. Proposals include electing six directors, ratifying Deloitte & Touche LLP, an advisory say-on-pay vote and say-on-pay frequency, and governance items.
The company seeks approval to amend its 2024 Equity Incentive Plan to increase the share reserve by 9,600,000 shares and to amend its certificate of incorporation to raise authorized common stock to either 60,000,000 or 300,000,000 shares, depending on a separate reverse stock split outcome. SCYNEXIS had 79,442,633 shares of common stock outstanding and entitled to vote as of April 27, 2026.
SCYNEXIS, Inc. Schedule 13G shows CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. report beneficial ownership of 3,008,874 shares of SCYNEXIS common stock, representing 6.7% of the class. The reported shares consist of warrants exercisable subject to 4.99% and 9.99% ownership caps. Shares outstanding were 41,924,941 as of August 8, 2025.
SCYNEXIS, Inc. is calling a virtual special stockholder meeting on May 19, 2026 to seek approval for a reverse stock split of its common stock at a ratio between 1‑for‑5 and 1‑for‑10, along with a proportional reduction in authorized shares. The board states this flexibility is intended to help the company regain compliance with The Nasdaq Capital Market’s minimum bid price requirement before June 15, 2026 and avoid potential delisting proceedings. As of April 20, 2026, the company had 79,442,633 common shares outstanding and 150,000,000 authorized, which would all be reduced proportionately if the split is implemented.